What Tisseel Treats: Main Uses and Benefits

Tisseel is applied across domains where additional symptomatic support is needed in relation to acute surgical challenges. It is commonly used as an adjunct to hemostasis in surgical procedures where localized bleeding cannot be effectively controlled by standard techniques, as well as for addressing the symptomatic concern of risk of leakage and instability of grafts.

This product is relevant for managing conditions characterized by persistent blood flow or tissue instability, offering supportive relief that may help patients cope more steadily with recovery. The product contributes to providing a localized clotting solution to secure the surgical site, particularly when the patient's natural clotting ability is reduced due to prescribed medications.

Quick Fact: Supportive Management for Surgical Contexts

Domain	Conditions/Symptom Clusters	Patient-Oriented Benefit
Hemostasis	Localized bleeding when standard techniques are insufficient	Contributes to maintaining functional stability during the operation
Sealing	Risk of leakage (CSF, anastomotic, fistula formation)	Supports patients during difficult episodes by easing physiological strain
Adhesion	Instability of grafts, meshes, or fragile tissue	Contributes to the support of structural integrity in the surgical closure

Regulatory References

1. Medsafe New Zealand Data Sheet

Who Can and Cannot Use Tisseel?

Population eligibility for Tisseel is determined by official regulatory labeling, which establishes both patient groups allowed for use and those who are strictly prohibited.

Absolute Prohibitions (Contraindications)

Use of Tisseel is contraindicated in patients with a known hypersensitivity to the product, including its component Aprotinin. The product must never be applied intravascularly (injected into the circulatory system). Additionally, it is prohibited for treating severe or brisk arterial or venous bleeding as the efficacy is not established in this setting.

Population-Specific Eligibility

Population Group	Regulatory Status
Pediatric Patients	Approved for those older than 1 month of age. Safety and effectiveness are not established in infants younger than 1 month.
Pregnancy	Use is restricted and permitted only if clearly needed, due to the absence of adequate human studies.
Lactation	Requires caution, as data regarding the presence in human milk are not available.
Geriatric Patients	No geriatric-specific problems or restrictions are documented compared to younger adults.

Safety and effectiveness have not been evaluated for use in neurosurgical procedures or surgeries within confined spaces.

Interactions with other medicines and products

Official regulatory documents indicate that systemic drug-drug interactions, such as those involving metabolic enzymes or plasma exposure, are not known for Tisseel due to its exclusive topical application. No formal interaction studies have been performed, and no known systemic interactions with orally or parenterally administered medicinal products are documented.

Local Incompatibilities and Efficacy Constraints

Interactions documented in regulatory labeling are confined to the application site, concerning chemical incompatibilities and effects on product function:

• Local Chemical Inactivation: Tisseel must not be mixed with other medicinal products. Furthermore, the active components (Sealer Protein and Thrombin Solutions) are denatured by contact with solutions containing alcohol, iodine, or heavy metals. This chemical inactivation interferes with the product's ability to form a functional seal.
• Efficacy Reduction: Oxidized cellulose-containing preparations are documented to reduce the efficacy of Tisseel. Regulatory restrictions prohibit the use of these preparations as carrier materials for Tisseel.
• Timing Requirements: If denaturing substances such as alcohol or iodine were used for wound preparation, the application area must be thoroughly rinsed before Tisseel is applied to ensure the product’s integrity and function.

Notably, Tisseel can be applied in fully heparinised patients, as stated in official labeling.

Tisseel's mechanism of action involves the localized co-administration of fibrinogen and thrombin components. Thrombin, a serine protease, acts catalytically on its biological target, fibrinogen. This interaction is an enzymatic cleavage, specifically removing the fibrinopeptides A and B from the central E-domain of the fibrinogen molecule.

This proteolytic cleavage converts soluble fibrinogen into fibrin monomers. These monomers spontaneously self-assemble via knob-hole interactions into two-stranded protofibrils. These protofibrils then undergo lateral aggregation to form a dense, three-dimensional fibrin matrix or clot network at the site of administration.

Simultaneously, thrombin also acts as a catalytic agonist on Factor XIII (fibrin stabilizing factor) in the presence of calcium ions, converting it to its active form, Factor XIIIa. Factor XIIIa is a transglutaminase that catalyzes the formation of covalent epsilon-( gamma-glutamyl)lysine cross-links between the fibrin strands. This intermolecular cross-linking stabilizes the initial fibrin polymer, leading to the systemic-level physiological consequence of localized mechanical support and tissue adhesion via the established matrix.

How Tisseel is Used: Official Administration and Instructions

Tisseel is a specialized, prescription-only product administered exclusively by qualified healthcare professionals within a surgical or hospital setting. Its use is strictly defined by regulatory guidelines to ensure precise and correct application during an operation.

---

Official Routes and Dosing Principles

Instruction Category	Regulatory Requirement
Route of Administration	Topical use only. The product is applied directly to the surface of the tissue. It must not be injected intravascularly (into a blood vessel) or into highly vascularized tissue.
Dosing Principle	There is no fixed dose. The required amount is determined by the size of the surgical area to be treated. Surgeons apply a thin layer sufficient to cover the entire target surface to avoid issues with wound healing.
Dosing Frequency	Typically a single application is performed during the surgical procedure. Re-application is possible if needed, provided the original clot residues are removed and the site is dried before the second application.

---

Preparation and Procedural Requirements

Successful use relies on critical preparation steps prior to application:

• Thawing and Warming: The two separate components are supplied frozen and must be fully thawed and warmed to a temperature between 33 °C and 37 °C before use.
• Simultaneous Application: The components must be dispensed simultaneously using the specialized dual-syringe applicator system onto a dried surgical site. Separate, sequential application is explicitly prohibited.
• Use Window: Once warmed, the product must be used within a defined period (typically 4 to 12 hours, depending on the specific product formulation) and any remainder must be discarded.

Use in Specific Populations

Tisseel is indicated for use in Adult and Pediatric Patients, including infants greater than one month of age, when undergoing surgical procedures.

Research Evidence: Overview of Studies for Tisseel

Evidence for Use as an Adjunct to Hemostasis in Complex Surgery

The central goal of clinical trials, primarily Randomized Controlled Trials (RCTs), was studied for how quickly bleeding could be controlled when standard surgical techniques were not fully effective. Research has examined Tisseel's use in major operations, such as cardiac and vascular surgery, and the studies monitored the time until complete hemostasis (cessation of bleeding) was achieved. Trials described patterns where a higher percentage of patients who received Tisseel achieved this endpoint within short, predefined timeframes compared to control groups receiving standard care. These observations included patients who were fully heparinized (receiving blood-thinning medication).

Evidence for Use in Surgical Sealing and Leak Prevention

Research has also explored Tisseel's role as a sealant. In neurosurgery, research examined the incidence of Cerebrospinal Fluid (CSF) leakage following procedures involving the dura mater. Findings were mixed across systematic reviews; while some comparative trials described patterns of lower incidence of CSF leakage, other analyses reported no statistically discernible difference in the overall postoperative leakage rate between sealant-supported closure and primary closure alone. Evidence quality varies across studies due to differences in surgical approach.

Key Research Gaps and Uncertainties

The majority of studies focused on immediate outcomes, meaning the long-term effects are not fully established regarding the integrity of the treated site or functional recovery. Follow-up durations were limited in many key trials. Additionally, comparative evidence is sometimes lacking, and data for certain groups remain insufficient, such as for patients with rare coagulopathies. The consistency of research results remains varied across different surgical contexts.

Common questions about Tisseel (FAQ)

---

Q: How long does TISSEEL stay in the body or on the tissue? Does it get absorbed?

Official product information describes the fibrin clot that TISSEEL forms as biodegradable, meaning it is designed to be naturally broken down and resorbed by the body. The absorption process occurs as part of normal wound healing, which typically takes a period of days to weeks following the surgical procedure.

Q: Does TISSEEL come in different versions or strengths?

TISSEEL is manufactured with the same core formulation, but it is provided in several different total volume packages. According to the official prescribing information, it is supplied in volumes such as 2 mL, 4 mL, and 10 mL. This variety indicates that the product is available in different package sizes, which are chosen by the surgical team based on the required area of application.

Q: Is a stinging or burning sensation at the application site a common side effect?

Stinging or burning at the site of application has been reported in post-marketing safety data for TISSEEL. Official safety information indicates that these sensations may be linked to a hypersensitivity or allergic type of reaction. The management of any unexpected pain or reaction during or after application is addressed by the healthcare team.

Q: Can TISSEEL be used for non-surgical wounds or without an incision, like deep cuts?

Regulatory documents clarify that TISSEEL is specifically indicated for use as an adjunctive treatment in patients undergoing surgery. The product is strictly for topical use on internal surgical sites. It is not intended for injection into blood vessels or for use on non-surgical wounds or cuts.

Q: Is there a maximum amount of TISSEEL that can be used on a patient?

There is no single, fixed dose of TISSEEL, as the amount is determined by the specific surface area of the wound being treated. The official prescribing label provides details on the maximum coverage area for each of the available package sizes when applied as a thin layer. Official guidelines for administration indicate that the minimum amount necessary should be used to cover the entire target surface.

Q: How is TISSEEL manufactured to ensure sterility and safety from infectious agents?

TISSEEL is a biologic product, meaning some components are derived from pooled human plasma. To enhance safety, regulatory documents require the components to undergo specific manufacturing steps, such as vapor heating and solvent/detergent treatment. These processes are designed to reduce the risk of transmitting infectious agents.

Q: Does TISSEEL have any antimicrobial properties to prevent infection?

TISSEEL is regulated as a fibrin sealant and hemostatic agent, meaning its purpose is to stop bleeding and seal tissue. Official prescribing information does not include an indication that the product has specific antimicrobial properties. Its use is focused on creating a physical barrier to support hemostasis and wound closure.

Q: Can TISSEEL be used in dental or oral surgery procedures?

TISSEEL is generally approved for use as an adjunct to stop bleeding in patients undergoing surgery in various locations. While its use is not completely restricted from all surgical sites, official warnings specifically contraindicate its injection into highly vascularized tissues. The decision on the appropriateness of TISSEEL is made by the surgical team based on the specific anatomical site and regulatory restrictions.

Q: Is TISSEEL safe for use in patients with liver disease or bleeding disorders (coagulopathy)?

Official regulatory information states that TISSEEL has been shown to be effective in patients who are heparinized (receiving a common blood-thinning medication). However, the documentation does not contain specific information addressing the safety profile or effectiveness for patients with severe liver disease or other specific, complex coagulopathies.

Q: Do I need special post-operative monitoring after TISSEEL application?

Post-operative monitoring is determined by the surgical procedure and the patient’s overall condition. Official product information describes that when TISSEEL is applied using a spray device, monitoring of vital signs (such as blood pressure and pulse) may be necessary. This monitoring helps the surgical team watch for potential complications, such as air or gas embolism, and signs of a rare hypersensitivity reaction.

Q: Does TISSEEL have a boxed warning, which is the most serious type of warning from the FDA?

The official FDA Prescribing Information for TISSEEL does not include a Boxed Warning (also known as a Black Box Warning). This type of regulatory caution is reserved for drug products that carry the most severe safety risks documented in clinical trials.

Q: Does TISSEEL contain any bovine (cow) or animal-derived components?

Official descriptions confirm that the active components, the sealer protein and thrombin, are derived from pooled human plasma. The fibrinolysis inhibitor, Synthetic Aprotinin, is manufactured from materials confirmed to be completely of non-human and non-animal origin.

Storage and Disposal of TISSEEL (Fibrin Sealant)

TISSEEL is a biologic product requiring strict adherence to officially documented storage rules to ensure stability.

Mandatory Storage Conditions

Item	Requirement
Temperature	Store continuously in a deep freezer at -18 C or colder (or leq -20 C) to maintain the cold chain.
Protection	Keep in the original outer carton to protect the solution from light.
Prohibited	Do not refreeze or refrigerate after the product has been thawed.
Child Safety	Must be kept out of the reach and sight of children.

Stability and Disposal Rules

Thawed, unopened product may be stored at leq 25 C for a maximum of 72 hours. The product is for single use only, and any unused solution must be discarded. Disposal of unused or expired TISSEEL must be carried out in accordance with local medicinal waste regulations.